Prostate-specific antigen response after definitive radiotherapy for Skene's gland adenocarcinoma resembling prostate adenocarcinoma

Timothy P. Korytko, Gregory J. Lowe, Rafael E Jimenez, Kamal S. Pohar, Douglas D. Martin

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objectives: To assess prostate-specific antigen response after definitive radiotherapy in a patient with localized Skene's gland adenocarcinoma resembling prostate adenocarcinoma. Materials and methods: A 71-year-old patient was evaluated for a 2 year history of painless hematuria and found to have a localized Skene's gland adenocarcinoma resembling prostate adenocarcinoma with a pre-therapy PSA of 54.52 ng/ul. She elected to undergo definitive radiotherapy holding radical surgery for salvage. She received 73.8 Gy of intensity modulated radiotherapy in 41 fractions. Serum PSA, imaging, and cystoscopy were followed at 6 month intervals for 2.5 years. Results: The PSA decreased to 0.65 ng/ul 32 months after treatment, her clinical symptoms resolved, and on imaging and exam she has no evidence of residual disease. The PSA half life was 6.16 months (r2 = 0.97). Conclusions: For this rare tumor we show that PSA is a reliable marker for disease response and also show that definitive radiotherapy can be an option for organ and functional preservation in patients with localized disease. Cases of periurethral adenocarcinomas should be pathologically screened to assess if they are of Skene's gland origin, as our results suggest a radiotherapy treatment paradigm may be appropriate management in a select subgroup of women with periurethral adenocarcinoma.

Original languageEnglish (US)
Pages (from-to)602-606
Number of pages5
JournalUrologic Oncology: Seminars and Original Investigations
Volume30
Issue number5
DOIs
StatePublished - Sep 2012
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
Prostate
Adenocarcinoma
Radiotherapy
Organ Preservation
Intensity-Modulated Radiotherapy
Cystoscopy
Hematuria
Half-Life
Therapeutics
Serum
Neoplasms

Keywords

  • Periurethral adenocarcinoma
  • Prostate-specific antigen
  • Radiotherapy
  • Skene's gland

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Prostate-specific antigen response after definitive radiotherapy for Skene's gland adenocarcinoma resembling prostate adenocarcinoma. / Korytko, Timothy P.; Lowe, Gregory J.; Jimenez, Rafael E; Pohar, Kamal S.; Martin, Douglas D.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 30, No. 5, 09.2012, p. 602-606.

Research output: Contribution to journalArticle

@article{5d196731ded94747ad93232df3344edf,
title = "Prostate-specific antigen response after definitive radiotherapy for Skene's gland adenocarcinoma resembling prostate adenocarcinoma",
abstract = "Objectives: To assess prostate-specific antigen response after definitive radiotherapy in a patient with localized Skene's gland adenocarcinoma resembling prostate adenocarcinoma. Materials and methods: A 71-year-old patient was evaluated for a 2 year history of painless hematuria and found to have a localized Skene's gland adenocarcinoma resembling prostate adenocarcinoma with a pre-therapy PSA of 54.52 ng/ul. She elected to undergo definitive radiotherapy holding radical surgery for salvage. She received 73.8 Gy of intensity modulated radiotherapy in 41 fractions. Serum PSA, imaging, and cystoscopy were followed at 6 month intervals for 2.5 years. Results: The PSA decreased to 0.65 ng/ul 32 months after treatment, her clinical symptoms resolved, and on imaging and exam she has no evidence of residual disease. The PSA half life was 6.16 months (r2 = 0.97). Conclusions: For this rare tumor we show that PSA is a reliable marker for disease response and also show that definitive radiotherapy can be an option for organ and functional preservation in patients with localized disease. Cases of periurethral adenocarcinomas should be pathologically screened to assess if they are of Skene's gland origin, as our results suggest a radiotherapy treatment paradigm may be appropriate management in a select subgroup of women with periurethral adenocarcinoma.",
keywords = "Periurethral adenocarcinoma, Prostate-specific antigen, Radiotherapy, Skene's gland",
author = "Korytko, {Timothy P.} and Lowe, {Gregory J.} and Jimenez, {Rafael E} and Pohar, {Kamal S.} and Martin, {Douglas D.}",
year = "2012",
month = "9",
doi = "10.1016/j.urolonc.2010.06.015",
language = "English (US)",
volume = "30",
pages = "602--606",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Prostate-specific antigen response after definitive radiotherapy for Skene's gland adenocarcinoma resembling prostate adenocarcinoma

AU - Korytko, Timothy P.

AU - Lowe, Gregory J.

AU - Jimenez, Rafael E

AU - Pohar, Kamal S.

AU - Martin, Douglas D.

PY - 2012/9

Y1 - 2012/9

N2 - Objectives: To assess prostate-specific antigen response after definitive radiotherapy in a patient with localized Skene's gland adenocarcinoma resembling prostate adenocarcinoma. Materials and methods: A 71-year-old patient was evaluated for a 2 year history of painless hematuria and found to have a localized Skene's gland adenocarcinoma resembling prostate adenocarcinoma with a pre-therapy PSA of 54.52 ng/ul. She elected to undergo definitive radiotherapy holding radical surgery for salvage. She received 73.8 Gy of intensity modulated radiotherapy in 41 fractions. Serum PSA, imaging, and cystoscopy were followed at 6 month intervals for 2.5 years. Results: The PSA decreased to 0.65 ng/ul 32 months after treatment, her clinical symptoms resolved, and on imaging and exam she has no evidence of residual disease. The PSA half life was 6.16 months (r2 = 0.97). Conclusions: For this rare tumor we show that PSA is a reliable marker for disease response and also show that definitive radiotherapy can be an option for organ and functional preservation in patients with localized disease. Cases of periurethral adenocarcinomas should be pathologically screened to assess if they are of Skene's gland origin, as our results suggest a radiotherapy treatment paradigm may be appropriate management in a select subgroup of women with periurethral adenocarcinoma.

AB - Objectives: To assess prostate-specific antigen response after definitive radiotherapy in a patient with localized Skene's gland adenocarcinoma resembling prostate adenocarcinoma. Materials and methods: A 71-year-old patient was evaluated for a 2 year history of painless hematuria and found to have a localized Skene's gland adenocarcinoma resembling prostate adenocarcinoma with a pre-therapy PSA of 54.52 ng/ul. She elected to undergo definitive radiotherapy holding radical surgery for salvage. She received 73.8 Gy of intensity modulated radiotherapy in 41 fractions. Serum PSA, imaging, and cystoscopy were followed at 6 month intervals for 2.5 years. Results: The PSA decreased to 0.65 ng/ul 32 months after treatment, her clinical symptoms resolved, and on imaging and exam she has no evidence of residual disease. The PSA half life was 6.16 months (r2 = 0.97). Conclusions: For this rare tumor we show that PSA is a reliable marker for disease response and also show that definitive radiotherapy can be an option for organ and functional preservation in patients with localized disease. Cases of periurethral adenocarcinomas should be pathologically screened to assess if they are of Skene's gland origin, as our results suggest a radiotherapy treatment paradigm may be appropriate management in a select subgroup of women with periurethral adenocarcinoma.

KW - Periurethral adenocarcinoma

KW - Prostate-specific antigen

KW - Radiotherapy

KW - Skene's gland

UR - http://www.scopus.com/inward/record.url?scp=84866764966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866764966&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2010.06.015

DO - 10.1016/j.urolonc.2010.06.015

M3 - Article

C2 - 20870432

AN - SCOPUS:84866764966

VL - 30

SP - 602

EP - 606

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 5

ER -